Antibody-Drug Conjugates Are ‘Changing Outcomes’ in HR+ HER2– Breast Cancer
June 7th 2023Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.